Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease

Neurobiology of Disease

Volumn 6, Issue 6, 1999, Pages 461-474

  Andersson, M ^a   Hilbertson, A ^a   Cenci, M A ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; LEVODOPA; MESSENGER RNA; PRODYNORPHIN; TRANSCRIPTION FACTOR FOSB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG INDUCED DISEASE; DYSKINESIA; FEMALE; INVOLUNTARY MOVEMENT; LONG TERM CARE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RAT;

EID: 0033428178     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1999.0259     Document Type: Article

References (42)

1. Abercrombie U. Estimation of nuclear populations from microtome sections. Brain Res. 94:1946;239-247.
2. Albin R. L., Young A. B., Penney J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
3. Andrews N. C., Faller D. V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:1991;2499.
4. Berke J. D., Paletzki R. F., Aronson G. J., Hyman S. E., Gerfen C. R. A complex program of striatal gene expression induced by dopaminergic stimulation. J. Neurosci. 18:1998;5301-5310.
5. Brotchie J. M., Henry B., Hille C. J., Crossman A. R. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Fahn S., Marsden C. D., DeLong M. R. Advances in Neurology, Dystonia 3. 1998;41-52 Lippincott-Raven, New York.
6. Brown J. R., Ye H., Bronson R. T., Dikkes P., Greenberg M. E. A defect in nurturing in mice lacking the immediate early gene FosB. Cell. 86:1996;297-309.
7. 2 dopamine receptor cDNA. Nature. 336:1988;783-787.
8. Carey R. J. Naloxone reverses l-DOPA induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci. 48:1991;1303-1308.
9. Cenci M. A., Lee C. S., Björklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:1998;2694-2706.
10. Cenci M. A., Tranberg A., Andersson M., Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-DOPA treatment. Neuroscience. 1999.
11. Chen J., Kelz M. B., Hope B. T., Nakabeppu Y., Nestler E. J. Chronic Fos-related antigens: Stable variants of ΔFosB induced in brain by chronic treatments. J. Neurosci. 17:1997;4933-4941.
12. Civelli O., Douglas J., Godstein A., Herbert E. Sequence and expression of the rat prodynorphin gene. Proc. Natl. Acad. Sci. USA. 82:1985;4291-4295.
13. Clarke C. E., Boyce S., Robertson R. G., Sambrook M. A., Crossman A. R. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neurol. Sci. 90:1989;307-314.
14. Cole R. L., Konradi C., Douglass J., Hyman S. E. Neuronal adaptation to amphetamine and dopamine: Molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron. 14:1995;813-823.
15. Collins-Hicok J., Lin L., Spiro C., Laybourn P. J., Tschumper R., Rapacz B., McMurray C. T. Induction of the rat prodynorphin gene through Gs-coupled receptors may involve phosphorylation-dependent derepression and activation. Mol. Cell. Biol. 14:1994;2837-2848.
16. Crocker S. J., Morelli M., Wigle N., Nakabeppu Y., Robertson G. S. D1-receptor-related priming is attenuated by antisense-mediated knockdown of fosB expression. Mol. Brain Res. 53:1998;69-77.
17. Dickson P. R., Lang C. G., Hinton S. C., Kelley A. E. Oral stereotypy induced by amphetamine microinjection into striatum: An anatomical mapping study. Neuroscience. 61:1994;81-91.
18. Dobrzanski P., Noguchi K., Kovary K., Rizzo C. A., Lazo P. S., Bravo R. Both products of the fosB gene, FosB and its short form, FosB/SF, are transcriptional activators in fibroblasts. Mol. Cell. Biol. 11:1991;5470-5478.
19. Doucet J.-P., Nakabeppu Y., Bedard P. J., Hope B. T., Nestler E. J., Jasmin B. J., Chen J.-S., Iadarola M. J., St-Jean M., Wigle N., Blanchet P., Grondin R., Robertson G. S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of delta-FosB-like proteins in both the rodent and primate striatum. Eur. J. Neurosci. 8:1996;365-381.
20. Ehrlich M. E., Kurihara T., Greengard P. Rat DARPP-32: Cloning, sequencing, and characterization of cDNA. J. Mol. Neurosci. 2:1990;1-10.
21. Gruda M. C., van Amsterdam J., Rizzo C. A., Durham S. K., Lira S., Bravo R. Expression of FosB during mouse development: Normal development of FosB knockout mice. Oncogene. 12:1996;2177-2185.
22. Hope B. T. Cocaine and the AP-1 transcription factor complex. Ann. N. Y. Acad. Sci. 844:1998;1-6.
23. Hope T. B., Nye H. E., Kelz M. B., Self D. W., Iadarola M. J., Nakabeppu Y., Duman R. S., Nestler E. J. Induction of a long-lasting AP1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 13:1994;1235-1244.
24. Howells R. D., Kilpatrick D. L., Bhatt R., Monahan J. J., Poonian M., Udenfriend S. Molecular cloning and sequence determination of rat preproenkephaline cDNA: Sensitive probe for studying transcriptional changes in rat tissues. Proc. Natl. Acad. Sci. USA. 81:1984;7651-7655.
25. Kirik D., Rosenblad C., Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152:1998;259-277.
26. Kirk R. E. Experimental Design: Procedures for the Behavioral Sciences. 1968;Brooks/Cole, Belmont.
27. Kobayashi Y., Kaufman D. L., Tobin A. J. Glutamic acid decarboxylase cDNA: Nucleotide sequence encoding an enzymatically active fusion protein. J. Neurosci. 7:1987;2768-2772.
28. Lavin A., Garcia-Munoz M. Electrophysiological changes in substantia nigra after dynorphin administration. Brain Res. 369:1985;298-302.
29. Liu F.-C., Graybiel A. M. Spatiotemporal dynamics of CREB phosphorylation: Transient versus sustained phosphorylation in the developing striatum. Neuron. 17:1996;1133-1144.
30. Mouradian M. M., Heuser I. J. E., Baronti F., Fabbrini G., Juncos J. L., Chase T. N. Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 25:1989;523-526.
31. Naranjo J. R., Mellström B., Achaval M., Sassone-Corsi P. Molecular pathways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene. Neuron. 6:1991;607-617.
32. Newman D. D., Rajakumar N., Flumerfelt B. A., Stoessl A. J. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. NeuroReport. 8:1997;669-672.
33. Nutt J. G. Levodopa-induced dyskinesia: Review, observations and speculations. Neurology. 40:1990;340-345.
34. Nutt J. G. Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson's disease. Lang A. E., Weiner W. J. Drug-Induced Movement Disorders. 1992;Futura.
35. Piccini P., Weeks R. A., Brooks D. J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol. 42:1997;720-726.
36. Pisa M. Motor functions of the striatum in the rat: Critical role of the lateral region in tongue and forelimb reaching. Neuroscience. 24:1988;453-463.
37. Reisine T., Pasternak G. Opioid analgesics and antagonists. Hardman J. G., Limbird L. E. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 1996;521-527 McGraw-Hill, New York.
38. Salamone J. D., Mahan K., Rogers S. Ventrolateral striatal dopamine depletions impair feeding and food handling in rats. Pharmacol. Biochem. Behav. 44:1993;605-610.
39. Sandyk R., Snider S. N. Naloxone treatment of l-dopa-induced dyskinesias in Parkinson's disease. Am. J. Psychiatry. 143:1986;118.
40. Schneider J. S. Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to the extent of nigrostriatal damage. Pharmacol. Biochem. Behav. 34:1989;193-196.
41. Schwarting R. K. W., Huston J. P. The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50:1996;275-331.
42. Trabucchi M., Bassi S., Frattola L. Effect of naloxone on the "on-off" syndrome in patients receiving long-term levodopa therapy. Arch. Neurol. 39:1982;120-121.